On Sunday, Arcellx, Inc. (NASDAQ:ACLX) revealed new data from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma ...

Is Arcellx, Inc. (ACLX) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.

Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients Arcellx's Phase 2 trial of anito-cel in relapsed multiple ...

Barclays raised the firm’s price target on Arcellx (ACLX) to $115 from $73 and keeps an Overweight rating on the shares following a transfer of coverage. The firm sees an increased probability ...

In a report released yesterday, Judah Frommer from Morgan Stanley maintained a Buy rating on Arcellx Inc (ACLX – Research Report), with a price target of $111.00. Pick the best stocks and ...

Analyst Gil Blum from Needham reiterated a Buy rating on Arcellx Inc (ACLX – Research Report) and keeping the price target at $105.00. Pick the best stocks and maximize your portfolio ...

have been observed to date in more than 150 patients dosed with anito-cel. Price Action: ACLX stock is up 6.46% at $90.01 during the premarket session at last check Monday.

Tuesday, Stifel reiterated its Buy rating on shares of Arcellx Inc. (NASDAQ: ACLX) with a $122.00 price target. The firm's analyst commented on the recent data presented at the American Society of ...